Topical beta-blockers for the treatment of Paronychia
- Conditions
- Paronychia induced by EGFR inhibitors
- Registration Number
- JPRN-jRCTs031190018
- Lead Sponsor
- Watanabe Tomoya
- Brief Summary
Before the start of this study, we were unable to enroll enough patients due to a decrease in the frequency of EGFR inhibitors, early intervention of treatment of paronychia in each departments, and expansion of the indication for immune checkpoint inhibitors, resulting in fewer severe cases of paronychia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 0
(1) Patients over the age of 20 with Grade 2 of paronychia
caused by EGFR inhibitors
(2) Ambulatory patients can answer survey questions
(3) Patients must receive substantial and sufficient
explanation of the content of this trial in all its
aspects and provide.
(4) Patients with self-management of skin and nail care
(1) Patients with bronchial asthma, bronchospasm, chronic
obstructive pulmonary disease, and cardiac failure
(2) Patients who are deemed unsuitable for inclusion in the
study for any other reason based on the assessment by the
investigators
(3) Patients with allergy for cephem antibiotic
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison between complete response and partial response of<br>granuloma at week 8
- Secondary Outcome Measures
Name Time Method Safety and adverse effects during the trial period<br>Improvement of periungual erythema and granuloma at week 4<br>Improvement of periungual erythema and granuloma at week 8